Literature DB >> 21181477

R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma.

Susan C Williams, Matthias A Karajannis, Luis Chiriboga, John G Golfinos, Andreas von Deimling, David Zagzag.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21181477      PMCID： PMC3718252          DOI： 10.1007/s00401-010-0790-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  10 in total

1.  Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression.

Authors:  D Zagzag; H Zhong; J M Scalzitti; E Laughner; J W Simons; G L Semenza
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

2.  Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

Authors:  David Capper; Susanne Weissert; Jörg Balss; Antje Habel; Jochen Meyer; Diana Jäger; Ulrike Ackermann; Claudia Tessmer; Andrey Korshunov; Hanswalter Zentgraf; Christian Hartmann; Andreas von Deimling
Journal:  Brain Pathol       Date:  2009-10-27       Impact factor: 6.508

3.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

4.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

5.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Authors:  Marc Sanson; Yannick Marie; Sophie Paris; Ahmed Idbaih; Julien Laffaire; François Ducray; Soufiane El Hallani; Blandine Boisselier; Karima Mokhtari; Khe Hoang-Xuan; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

6.  Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis.

Authors:  Philippe Metellus; Bema Coulibaly; Carole Colin; Andre Maues de Paula; Alexandre Vasiljevic; David Taieb; Anne Barlier; Blandine Boisselier; Karima Mokhtari; Xiao Wei Wang; Anderson Loundou; Frederique Chapon; Sandrine Pineau; L'Houcine Ouafik; Olivier Chinot; Dominique Figarella-Branger
Journal:  Acta Neuropathol       Date:  2010-11-16       Impact factor: 15.887

7.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Authors:  Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins
Journal:  Neuro Oncol       Date:  2009-05-12       Impact factor: 12.300

Review 8.  Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics.

Authors:  G L Semenza
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

Review 9.  Oxygen sensing by HIF hydroxylases.

Authors:  Christopher J Schofield; Peter J Ratcliffe
Journal:  Nat Rev Mol Cell Biol       Date:  2004-05       Impact factor: 94.444

10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079
  10 in total
  38 in total

Review 1.  Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.

Authors:  Ovidiu C Andronesi; Otto Rapalino; Elizabeth Gerstner; Andrew Chi; Tracy T Batchelor; Dan P Cahill; A Gregory Sorensen; Bruce R Rosen
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 2.  Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.

Authors:  Changcun Guo; Christopher J Pirozzi; Giselle Y Lopez; Hai Yan
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

3.  EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.

Authors:  Le Zhang; Ying Liu; Mengning Wang; Zhenhai Wu; Na Li; Jinsong Zhang; Chuanwei Yang
Journal:  J Mol Cell Biol       Date:  2017-12-01       Impact factor: 6.216

Review 4.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.

Authors:  Patrick S Ward; Craig B Thompson
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 5.  To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.

Authors:  Bharathan Bhavya; C R Anand; U K Madhusoodanan; P Rajalakshmi; K Krishnakumar; H V Easwer; A N Deepti; Srinivas Gopala
Journal:  Cell Mol Neurobiol       Date:  2019-09-04       Impact factor: 5.046

6.  Hypoxia-inducible factor-1-regulated protein expression and oligodendroglioma patient outcome: comparison with established biomarkers and preoperative UCSF low-grade scoring system.

Authors:  Shirley Abraham; Nan Hu; Randy Jensen
Journal:  J Neurooncol       Date:  2012-03-06       Impact factor: 4.130

7.  Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.

Authors:  Shingo Takano; Yukinari Kato; Tetsuya Yamamoto; Mika Kato Kaneko; Eiichi Ishikawa; Yuta Tsujimoto; Masahide Matsuda; Kei Nakai; Ryo Yanagiya; Shunpei Morita; Koji Tsuboi; Akira Matsumura
Journal:  J Neurooncol       Date:  2012-03-07       Impact factor: 4.130

Review 8.  Neomorphic mutations create therapeutic challenges in cancer.

Authors:  V Takiar; C K M Ip; M Gao; G B Mills; L W T Cheung
Journal:  Oncogene       Date:  2016-11-14       Impact factor: 9.867

Review 9.  Pheochromocytoma: Gasping for Air.

Authors:  Ivana Jochmanová; Zhengping Zhuang; Karel Pacak
Journal:  Horm Cancer       Date:  2015-07-03       Impact factor: 3.869

Review 10.  IDH mutations in human glioma.

Authors:  Won Kim; Linda M Liau
Journal:  Neurosurg Clin N Am       Date:  2012-05-31       Impact factor: 2.509
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.